Literature DB >> 18769935

Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses.

Wataru Komaki1, Tsuyoshi Fukushima, Hiroyuki Tanaka, Hiroshi Itoh, Etsuo Chosa, Hiroaki Kataoka.   

Abstract

Hepatocyte growth factor activator inhibitor type 1 (HAI-1)/spint-1 is a membrane-bound protease inhibitor that is thought to regulate the activities of hepatocyte growth factor activator, matriptase, hepsin, and prostasin. In this study, we show that the membrane form of HAI-1 was significantly upregulated immunohistochemically in epithelial cells under adverse conditions including tissue injury, necroinflammatory reactions, and invasion of carcinomas. To analyze the mechanism underlying these in vivo observations, we examined the effects of hypoxia and oxidative stress on HAI-1 expression in vitro, using three human cell lines, HLC-1, WiDr, and HeLa. Hypoxic condition significantly enhanced the expression of HAI-1 in these cells. Oxidative stress also enhanced HAI-1 expression. Promoter analyses of the human HAI-1/spint-1 gene revealed overlapping binding site for Egr-1-3 and Sp1 near the transcription start site as the key domain for HAI-1/spint-1 transcription. This site was also critical in both hypoxic- and oxidative stress-induced HAI-1 upregulation. In fact, in vivo immunohistochemical studies indicated that areas with HAI-1 upregulation tended to express markers associated with hypoxia and oxidative stress. These observations suggest that the tissue microenvironment regulates the cell surface expression of HAI-1, and thereby may regulate proteolysis and processing of bioactive molecules on the cellular surface.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769935     DOI: 10.1007/s00428-008-0662-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  34 in total

1.  MANSC: a seven-cysteine-containing domain present in animal membrane and extracellular proteins.

Authors:  Jinhu Guo; Shuai Chen; Chaoqun Huang; Li Chen; David J Studholme; Shouyuan Zhao; Long Yu
Journal:  Trends Biochem Sci       Date:  2004-04       Impact factor: 13.807

2.  Expression of hepatocyte growth factor activator inhibitor type 1 in endothelial cells.

Authors:  Yutaka Akiyama; Miyuki Nagai; Wataru Komaki; Kousuke Marutsuka; Yujiro Asada; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2006-08       Impact factor: 4.174

3.  Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.

Authors:  Daniele Generali; Stephen B Fox; Alfredo Berruti; John W Moore; Maria Pia Brizzi; Nilay Patel; Giovanni Allevi; Simone Bonardi; Sergio Aguggini; Alessandra Bersiga; Leticia Campo; Luigi Dogliotti; Alberto Bottini; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 4.  Hepsin and prostate cancer.

Authors:  Qingyu Wu; Gordon Parry
Journal:  Front Biosci       Date:  2007-09-01

5.  Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

Authors:  Daniel Kirchhofer; Mark Peek; Michael T Lipari; Karen Billeci; Bin Fan; Paul Moran
Journal:  FEBS Lett       Date:  2005-03-28       Impact factor: 4.124

6.  Hypoxia-associated induction of early growth response-1 gene expression.

Authors:  S F Yan; J Lu; Y S Zou; J Soh-Won; D M Cohen; P M Buttrick; D R Cooper; S F Steinberg; N Mackman; D J Pinsky; D M Stern
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

Review 7.  Matriptase and its putative role in cancer.

Authors:  K Uhland
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

8.  Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.

Authors:  S L Lee; R B Dickson; C Y Lin
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 9.  Hypoxia-driven selection of the metastatic phenotype.

Authors:  Richard Sullivan; Charles H Graham
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

10.  The epidermal barrier function is dependent on the serine protease CAP1/Prss8.

Authors:  Céline Leyvraz; Roch-Philippe Charles; Isabelle Rubera; Marjorie Guitard; Samuel Rotman; Bernadette Breiden; Konrad Sandhoff; Edith Hummler
Journal:  J Cell Biol       Date:  2005-08-01       Impact factor: 10.539

View more
  5 in total

1.  Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Po-Sheng Yang; Ming-Nan Chien; Yuan-Ching Chang; Chi-Hsin Lin; Shih-Ping Cheng
Journal:  Histochem Cell Biol       Date:  2018-03-12       Impact factor: 4.304

2.  Tissue injury alters the site of expression of hepatocyte growth factor activator inhibitor type 1 in bronchial epithelial cells.

Authors:  Hiroyuki Tanaka; Tsuyoshi Fukushima; Kenji Yorita; Makiko Kawaguchi; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2009-02       Impact factor: 4.174

Review 3.  Mechanisms of hepatocyte growth factor activation in cancer tissues.

Authors:  Makiko Kawaguchi; Hiroaki Kataoka
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

4.  Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model.

Authors:  Jingjia Ye; Makiko Kawaguchi; Yukihiro Haruyama; Ai Kanemaru; Tsuyoshi Fukushima; Koji Yamamoto; Chen-Yong Lin; Hiroaki Kataoka
Journal:  Cancer Sci       Date:  2013-11-25       Impact factor: 6.716

5.  Intestinal regulation of suppression of tumorigenicity 14 (ST14) and serine peptidase inhibitor, Kunitz type -1 (SPINT1) by transcription factor CDX2.

Authors:  E Thomas Danielsen; Anders Krüger Olsen; Mehmet Coskun; Annika W Nonboe; Sylvester Larsen; Katja Dahlgaard; Eric Paul Bennett; Cathy Mitchelmore; Lotte Katrine Vogel; Jesper Thorvald Troelsen
Journal:  Sci Rep       Date:  2018-08-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.